Fig. 3.

RNA-seq analysis and the effect of canagliflozin on cell cycle in thyroid cancer. A–D RNA sequencing results: differential gene expression; GO term analysis; KEGG pathway analysis; GSEA. E, F Canagliflozin inhibited G1/S phase transition of TPC-1 and BCPAP cells. Cells were treated with 10 μM canagliflozin for 24 h, then the cell cycle was detected by flow cytometry. G Canagliflozin inhibited G1/S phase transition related protein expression. Cells were treated with 10 μM canagliflozin for 24 h, then cyclin D1-3, cyclin E1-2, E2F1-2 were detected by western blot. GAPDH was used as a loading control